How One Drug is Redefining Diabetes and Cardiovascular Care in The Indian Context

Review Article

How One Drug is Redefining Diabetes and Cardiovascular Care in The Indian Context

Dhammdeep C. Dabhade ^*

Department of Clinical Pharmacology, Mumbai, Maharashtra, India.

*Corresponding Author: Dhammdeep C. Dabhade, Department of Clinical Pharmacology, Mumbai, Maharashtra, India.

Citation: Dhammdeep C. Dabhade. (2025). How One Drug is Redefining Diabetes and Cardiovascular Care in The Indian Context, Journal of Clinical Cardiology and Cardiology Research, BioRes Scientia Publishers. 4(2):1-3. DOI: 10.59657/2837-4673.brs.25.050

Copyright: © 2025 Dhammdeep C. Dabhade, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: May 02, 2025 | Accepted: June 06, 2025 | Published: June 13, 2025

Abstract

Empagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged as a cornerstone in managing type 2 diabetes mellitus (T2DM), with significant cardiorenal benefits. As India continues to witness a dramatic surge in T2DM prevalence, understanding the real-world efficacy and safety of empagliflozin becomes paramount. This review explores its current clinical status and real-life evidence from Indian populations, and anticipates future therapeutic directions. Emphasis is placed on empirical data, physician experiences, and the practicalities of empagliflozin deployment across diverse healthcare settings in India.

Keywords: cardiovascular care; diabetes; India

Introduction

India, often dubbed the diabetes capital of the world, harbors over 77 million individuals with T2DM [1]. With this metabolic disorder becoming increasingly complex, especially with coexistent cardiovascular and renal complications, there is a pressing need for multi-dimensional therapies. Empagliflozin, originally approved for glycemic control, has redefined itself as a cardio-renal protective agent [2]. This narrative review delineates its clinical utility, practical implications, and potential trajectory in the Indian context.

Clinical Utility of Empagliflozin: Empagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting glycosuria. This insulin-independent mechanism not only lowers HbA1c levels but also induces weight loss and reduces systolic blood pressure [3]. Key clinical trials like EMPA-REG OUTCOME have demonstrated significant reductions in cardiovascular mortality and hospitalization for heart failure [4]. These benefits are particularly relevant in India, where T2DM patients often present late with multisystem involvement.

Clinical Efficacy - Global Evidence with Indian Relevance: The EMPA-REG OUTCOME trial was a landmark study demonstrating a 38% reduction in cardiovascular death and a 35% reduction in hospitalization for heart failure with empagliflozin in T2DM patients with established cardiovascular disease. Subsequent trials such as EMPEROR-Reduced and EMPEROR-Preserved expanded their utility in heart failure with reduced and preserved ejection fractions, respectively. These findings are particularly relevant in India where cardiovascular mortality is disproportionately high among diabetics. A multicentric observational study reported significant HbA1c reduction, weight loss, and blood pressure control in Indian patients initiated on empagliflozin [5]. Moreover, the Indian sub-study of the CVD-REAL 2 trial affirmed empagliflozin's superiority in reducing all-cause mortality and heart failure hospitalization in routine clinical settings.

Current Approval and Marketing Status of Empagliflozin in India

Empagliflozin has received multiple approvals in India for various indications. Initially approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In May 2022, the Central Drugs Standard Control Organisation (CDSCO) approved Empagliflozin for the treatment of heart failure, reducing the risk of cardiovascular death and hospitalization in adults with heart failure. In February 2024, CDSCO approved Jardiance 10mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with CKD at risk of progression. Following the expiration of Boehringer Ingelheim’s patent on March 1, 2025, several domestic pharmaceutical companies, have launched generic versions of empagliflozin in India at significantly reduced prices.

Challenges and Opportunities in Indian Real-Life Practice: Despite its proven benefits, empagliflozin uptake in India remains suboptimal. Factors include cost constraints, limited awareness among general practitioners, and therapeutic inertia. However, increasing inclusion in national and regional guidelines, along with generic availability, is expected to improve accessibility. Educating primary care providers, who manage the majority of Indian T2DM patients, is crucial. Integration of empagliflozin in the early stages of diabetes management, especially in patients with cardiovascular risk, can transform outcomes. Community-based screening and digital health interventions can play a pivotal role in expanding its use. Recent observational studies in India have corroborated empagliflozin's efficacy in reducing HbA1c (~1.0-1.2%), improving body weight, and reducing systolic blood pressure across urban and semi-urban populations [6,7]. Indian patients have shown good tolerability, with genital infections being the most commonly reported adverse event, albeit mild and self-limiting in most cases.

Cardiorenal Protection: A Game-Changer for Indian Physicians: In a country where access to advanced cardiology and nephrology care remains inconsistent, empagliflozin's potential to reduce cardiovascular events and slow kidney disease progression is monumental. Data from Indian cohorts in the CVD-REAL and EASE studies validate its safety profile and multi-system efficacy [8,9]. For practitioners managing patients in resource-limited settings, this dual utility simplifies therapy and enhances compliance.

Prescribing Patterns and Physician Insights: A recent multicenter survey of Indian diabetologists revealed increasing confidence in initiating empagliflozin as a second-line agent, particularly in overweight and hypertensive patients [10]. Physicians appreciated its low risk of hypoglycemia and ease of titration. However, cost concerns and patient awareness were noted barriers. Combining empagliflozin with metformin or DPP-4 inhibitors is becoming standard, especially in tertiary care centers.

Challenges and Considerations: While the therapeutic promise is high, certain challenges persist. Limited awareness among general practitioners, occasional misattribution of side effects, and regional disparities in drug availability hinder optimal uptake. There is also a need for pharmacovigilance data specific to the Indian populace, considering dietary, genetic, and climatic variations.

The Way Ahead - Future Directions in India: Empagliflozin's role is rapidly expanding beyond T2DM. Current trials are evaluating its utility in heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease irrespective of diabetes status [11]. India must invest in real-world registries and post-marketing surveillance to harness its full potential. Government-backed diabetes programs could consider empagliflozin for subsidized access, given its broad-spectrum benefits. Future Indian-centric research should focus on long-term outcomes, comparative effectiveness with other SGLT2 inhibitors, and subgroup analyses based on comorbid conditions. Registries and pharmacovigilance data from diverse regions can enrich understanding of real-world usage. The inclusion of empagliflozin in public health programs, especially for high-risk populations, could reduce the burden of complications and healthcare costs. Moreover, empagliflozin's role in type 1 diabetes, NAFLD, and polycystic ovary syndrome (PCOS) represents exciting frontiers worthy of exploration in the Indian context.

Conclusion

Empagliflozin has carved a niche in the management of T2DM, particularly for Indian patients who face an amplified burden of cardiovascular and renal complications. With its robust clinical profile and growing real-world evidence, empagliflozin represents a cornerstone therapy. Its use in the current clinical scenario seems to be a paradigm shift towards holistic management. With appropriate support, education, and infrastructure, empagliflozin can catalyze a new era in diabetes care in India.

References

International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th Ed.
Publisher | Google Scholor
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., et al. (2015). Empagliflozin, Cardiovascular Outcomes, And Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22):2117-2128.
Publisher | Google Scholor
Ferrannini, E. (2017). Sodium-Glucose Co-Transporters and Their Inhibition: Clinical Physiology. Cell Metabolism, 26(1):27-38.
Publisher | Google Scholor
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., et al. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 375(4):323-334.
Publisher | Google Scholor
Gupta, S., Shaikh, S., Joshi, P., Bhure, S., Suvarna, V. (2017). Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from A 76-Week Extension Trial of Phase III, Double-Blind, Randomized Study. Indian Journal of Endocrinology and Metabolism, 21(2):286-292.
Publisher | Google Scholor
Kumar, K. P., Unnikrishnan, A. G., Jariwala, P., Mehta, A., Chaturvedi, R., et al. (2024). SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care-An Indian Perspective. Indian Journal of Endocrinology and Metabolism, 28(1):11-18.
Publisher | Google Scholor
Singh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., et al. (2023). SGLT2i as a First-line Antihyperglycemic in the Management of Type 2 Diabetes in the Context of Indians: A Systematic Review and Consensus. The Journal of the Association of Physicians of India, 71(12):62-74.
Publisher | Google Scholor
Kosiborod, M., Lam, C. S., Kohsaka, S., Kim, D. J., Karasik, A., et al. (2018). Cardiovascular Events Associated with SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. Journal of the American College of Cardiology, 71(23):2628-2639.
Publisher | Google Scholor
Anjana, R. M., Unnikrishnan, R., Deepa, M., Pradeepa, R., Tandon, N., et al. (2023). Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). The Lancet Diabetes & Endocrinology, 11(7):474-489.
Publisher | Google Scholor
Jayaswal, S. K., Singh, S., Malik, P. S., Venigalla, S. K., Gupta, P., et al. (2021). Detrimental Effect of Diabetes and Hypertension on The Severity and Mortality of COVID-19 Infection: A Multi-Center Case-Control Study from India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(5):102248.
Publisher | Google Scholor
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., et al. (2021). Empagliflozin in Heart Failure with A Preserved Ejection Fraction. New England Journal of Medicine, 385(16):1451-1461.
Publisher | Google Scholor

Delia Teresa Sponza

"Journal of BioMed Research and Reports has created a diverse portfolio in peer review process and provides a wide range scientific and medical novel papers to the scientists. This journal publishes high-quality, peer-reviewed content across all levels of professional development and corporate research and development."

Fatema Tashrifwala

I would like to thank the editorial team for their timely responses and consideration in the publication of my paper. They have been very helpful and accommodating, Lastly, being an open access journal, the published work is freely available and accessible to readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nikhil Vitthal Dayama

I would like to thank the editorial team for their timely and prompt responses and consideration in the publication of my case report. Being an open access journal, it will be great help for the readers to learn the new things without any cost. I would encourage the authors to publish their research in BioRes Scientia and I am happy to be part of this journal.

Boubacar Ahy Diatta

I warmly thank the editorial team for the excellent work they do for continuing medical education in Dermatology. I was able to discover with joy their professionalist, their support and above all appreciate their social generosity on the access to the magazines which is free. This allows an update of scientific knowledge to the entire scientific community. I gladly recommend authors for publication in this journal.

Professor Rajko Igic

The editor of JBRR helped me during the whole process, mainly to eliminate some typographical and other errors. It hastened this publication to be published quickly. Although it is a short text, I believe that the content is important for all medical and other scientific disciplines because eventual addition of the iC citations to citation of the paper would lead to proper assessment of the author's contribution.

Dr Tewodros kassahun Tarekegn

I am thrilled to have had the opportunity to publish my research article in this prestigious journal. The entire process of peer review and publication support provided by the editorial office was exceptional, and it fortified my belief in the quality of my research study. The rigorous peer review process ensured that only the highest quality research was published, and the feedback from the reviewers was extremely helpful. I appreciate the journal's commitment to open access publication, enabling my research to reach a wider audience. The easy-to-use online platform streamlined the submission, peer review, and publication process, and I would confidently recommend this journal to any author looking for efficient, rigorous, and high-quality peer-reviewed publication.

Francis Okello Ooko

I was impressed by your author-centred approach whereby you maintained constant and timely communication with us from the time we submitted the manuscript to acceptance, each time providing critical suggestions to improve the manuscript. In addition, we are encouraged by the thoroughness of your editorial team in checking the originality and overall, quality of the work. Which I believe is very encouraging to other researchers and authors who wish to publish their work in your journals. The published work and the information imparted is freely available and accessible to a wide spectrum of readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nidhi Sapolia

I would like to thank the editorial team of their timely response and guidance in the publication of my case report. They have been extremely helpful at all stages. Being an open access journal, it is of great help for the readers to learn new experiences in different fields, I would highly recommend this journal to authors for high quality peer-reviewed publications.

Dwight L Mckee MD CNS ABIHM

I am very impressed by the high quality of the papers published by the International Journal of Clinical and Molecular Oncology. The editors of this journal are a pleasure to work with, as they are highly responsive even to numerous last minute changes in the manuscript that I recently published with them, and the changes are made on-line the same day they are received. I highly recommend this journal to anyone working in the oncology field, and also value it as a source of cutting edge information in the field.

Kyaw Swar Thet

I would like to thank the editorial team for the opportunity to publish our case report in this prestigious journal. I am very impressed by their timely and efficient handling of the submission, peer review, and publication processes. As residents of a developing, low-income country, we greatly appreciate the discount on submission charges. I hope that as an open access journal, it will facilitate easy access for readers to update their scientific knowledge. I highly recommend this journal for high-quality, peer-reviewed publications. I express my sincere gratitude to the editorial team for their excellent work.

Michel Farah

I would like to thank the editorial team for their quick response and support. The publication support and editorial office were excellent and very helpful. I am happy to have my research article published in this prestigious journal. Our previous case report published in this journal was very successful and viewed by many physicians worldwide.

Kristina Dimitrijevic

I am very positively surprised by thе International Journal of Biomedical and Clinical Research, as well as by the review process itself, which is carried out in a high-quality, timely and professional manner. I am glad that my articles are part of this journal.

Hamid Kasim

I had the pleasure of working with your esteemed journal. I testify that the peer review process was effective and quick, the support from the editorial office is very professional, respectful and friendly and the quality of the review is objective and accurate. I am grateful for the opportunity to work with International Journal of Biomedical & Clinical Research and looking forward for more future cooperation.

Ochala Ejura J

The interaction with the Journal of Women Health Care and Gynaecology has been seamless. I wish to express my profound appreciation to your expert editorial team for the timely response and support. The feedbacks from the peer review process was of great help. Thank you for the discount and opportunity to publish in your reputable journal. I believe that being an Open access journal, it will enable readers easy access to to update their knowledge. I would recommend BioRes Scientia publishers and look forward to more collaborations.

Fernando M Clara

I would like to thank the Journal of Clinical Cardiology and Cardiology Research for the opportunity to publish our work. We greatly appreciate the professionalism demonstrated throughout the editorial process. The rapid peer review, along with the high-quality graphic design, streamlined the process and significantly improved the final presentation of our manuscript. The Journal’s support for scientific dissemination is a meaningful incentive for ongoing research. We commend your editorial efforts and extend our best wishes for the Journal's continued success.

Dr Stylianos Sergios Chatziioannou

Journal of BioMed Research and Reports process was constructive and timely, ensuring that the scientific rigor of the manuscript was upheld. Communication with the editorial office was smooth and supportive throughout, making the overall publication experience very positive. I appreciate the efforts of the editorial team in maintaining high-quality standards, and I am confident that the journal will continue to grow in impact and recognition.

Dr C Zeroual

I am pleased to have worked with the Journal of Brain Research and Neurology. The editorial team was responsive and supportive throughout the process, and the peer review was handled efficiently. I appreciate the opportunity to contribute to this journal and look forward to future collaborations

Mohammadreza Kashefi Baher

I am pleased to have published my research in Dentistry and Oral Health Care. The peer review process was efficient and respectful, and I appreciated the timely communication and support from the editorial team. The journal maintains a professional standard and provides an accessible platform for sharing scientific work. I am grateful for the opportunity and look forward to contributing again in the future.

Cidalia De Fatima Cabral De Frias

I would like to thank the editorial team of International Journal of Biomedical and Clinical Research for their prompt and timely responses during the review process of my article. I had the opportunity to share with the academic community my understanding of the process of caring for a person at the end of life. I recommend the publication of research in the area of palliative care in this prestigious journal.

Roxana Maria Hoza

The peer review process at Hematology Research and Blood Disorders is fair and constructive. The editorial office provides excellent support and timely communication. The journal maintains high quality and is a trusted platform for hematology research.

Dr Hamid Kasim

I was very pleased to collaborate with your esteemed Journal of BioMed Research and Reports, and I also thank the editorial board and the reviewers who enriched my article with their very helpful comments, resulting in a beautiful and elegant presentation. I hope our collaboration will continue in the future, With my respect and best wishes for your continued success.